Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer
Omnicell, Inc. (Nasdaq: OMCL) has appointed Nnamdi Njoku as Executive Vice President and Chief Operating Officer, effective October 7, 2024. In this newly created role, Njoku will lead the company's global operations, reporting to Randall Lipps, chairman, president, CEO, and founder of Omnicell.
Njoku brings approximately 25 years of experience in leading global operations at healthcare and medical technology organizations. He most recently served as President of Sports Medicine, Surgical, Upper Extremities and Restorative Therapies at Zimmer Biomet Holdings, Inc. Previously, he spent over 18 years at Medtronic plc, where he led a $2 billion Neuromodulation Operating Unit.
Omnicell, a leader in transforming the pharmacy care delivery model, expects Njoku's expertise to help scale pharmacy automation and drive multi-year innovation and excellence.
Omnicell, Inc. (Nasdaq: OMCL) ha nominato Nnamdi Njoku come Vice Presidente Esecutivo e Direttore Operativo, con effetto dal 7 ottobre 2024. In questo nuovo ruolo, Njoku guiderà le operazioni globali dell'azienda, riportando a Randall Lipps, presidente, CEO e fondatore di Omnicell.
Njoku porta con sé circa 25 anni di esperienza nella guida delle operazioni globali in organizzazioni nel settore sanitario e della tecnologia medica. Più recentemente, ha ricoperto il ruolo di Presidente della Medicina Sportiva, Chirurgia, Estremità Superiori e Terapie Restorative presso Zimmer Biomet Holdings, Inc. In precedenza, ha trascorso oltre 18 anni presso Medtronic plc, dove ha guidato un'Unità Operativa di Neuromodulazione da 2 miliardi di dollari.
Omnicell, leader nella trasformazione del modello di assistenza farmaceutica, si aspetta che l'esperienza di Njoku aiuti a sviluppare l'automazione farmaceutica e a promuovere innovazioni e successi pluriennali.
Omnicell, Inc. (Nasdaq: OMCL) ha nombrado a Nnamdi Njoku como Vicepresidente Ejecutivo y Director de Operaciones, con efecto a partir del 7 de octubre de 2024. En este nuevo rol, Njoku liderará las operaciones globales de la empresa, reportando a Randall Lipps, presidente, CEO y fundador de Omnicell.
Njoku aporta aproximadamente 25 años de experiencia en la dirección de operaciones globales en organizaciones de tecnología médica y atención sanitaria. Recientemente, se desempeñó como presidente de Medicina Deportiva, Quirúrgica, Extremidades Superiores y Terapias Restaurativas en Zimmer Biomet Holdings, Inc. Anteriormente, pasó más de 18 años en Medtronic plc, donde lideró una Unidad de Neuromodulación de $2 mil millones.
Omnicell, líder en la transformación del modelo de atención farmacéutica, espera que la experiencia de Njoku ayude a escalar la automatización farmacéutica y a impulsar la innovación y la excelencia a largo plazo.
Omnicell, Inc. (Nasdaq: OMCL)는 Nnamdi Njoku를 이사 및 최고 운영 책임자(CEO)로 임명했습니다. 이는 2024년 10월 7일자로 효력이 발생합니다. Njoku는 이 새로운 역할에서 전 세계 운영을 이끌며, Omnicell의 회장 겸 CEO, 설립자인 Randall Lipps에게 보고할 것입니다.
Njoku는 의료 및 의료 기술 조직에서 전 세계 운영을 운영한 약 25년의 경험을 가지고 있습니다. 그는 최근 Zimmer Biomet Holdings, Inc.에서 스포츠 의학, 외과, 상지 및 회복 치료의 사장으로 재직했습니다. 이전에는 Medtronic plc에서 18년 이상 근무하며 20억 달러 규모의 신경 조절 운영 단위를 이끌었습니다.
Omnicell은 약국 서비스 제공 모델의 변화를 선도하며, Njoku의 전문성이 약국 자동화를 확장하고 다년간의 혁신과 우수성을 이끌 것으로 기대하고 있습니다.
Omnicell, Inc. (Nasdaq: OMCL) a nommé Nnamdi Njoku au poste de Vice-Président Exécutif et Directeur des Opérations, avec effet à compter du 7 octobre 2024. Dans ce nouveau rôle, Njoku dirigera les opérations mondiales de l'entreprise, rendant compte à Randall Lipps, président, CEO et fondateur d'Omnicell.
Njoku apporte environ 25 ans d'expérience dans la direction des opérations mondiales au sein d'organisations de technologie médicale et de soins de santé. Il a récemment occupé le poste de président de la médecine sportive, de la chirurgie, des membres supérieurs et des thérapies réparatrices chez Zimmer Biomet Holdings, Inc. Auparavant, il a passé plus de 18 ans chez Medtronic plc, où il a dirigé une unité d'exploitation de neuromodulation de 2 milliards de dollars.
Omnicell, leader dans la transformation du modèle de délivrance des soins pharmaceutiques, s'attend à ce que l'expertise de Njoku aide à étendre l'automatisation des pharmacies et à promouvoir l'innovation et l'excellence sur plusieurs années.
Omnicell, Inc. (Nasdaq: OMCL) hat Nnamdi Njoku zum Executive Vice President und Chief Operating Officer ernannt, wirksam ab dem 7. Oktober 2024. In dieser neu geschaffenen Rolle wird Njoku die globalen Operationen des Unternehmens leiten und an Randall Lipps, Vorsitzender, Präsident, CEO und Gründer von Omnicell, berichten.
Njoku bringt etwa 25 Jahre Erfahrung in der Leitung globaler Operationen in Gesundheits- und Medizintechnikorganisationen mit. Zuletzt war er Präsident für Sportmedizin, Chirurgie, obere Gliedmaßen und restorative Therapien bei Zimmer Biomet Holdings, Inc. Zuvor war er über 18 Jahre bei Medtronic plc tätig, wo er eine Betriebseinheit für Neuromodulation im Wert von 2 Milliarden Dollar leitete.
Omnicell, ein führendes Unternehmen in der Umgestaltung des Modells zur Bereitstellung von Apothekendiensten, erwartet, dass Njokus Fachwissen dabei hilft, die Automatisierung in Apotheken zu skalieren und mehrjährige Innovation und Exzellenz voranzutreiben.
- Appointment of an experienced executive with 25 years in healthcare and med tech
- New COO brings expertise in leading global operations and scaling businesses
- Potential for improved operational efficiency and innovation in pharmacy automation
- None.
The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence
Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024. In this newly created role, Mr. Njoku will lead the Company’s global operations. (Photo: Business Wire)
In this newly created role, Mr. Njoku will report to Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. Mr. Njoku will lead the Company’s global operations.
Mr. Njoku is a seasoned business executive with approximately 25 years of experience in leading global operations at several global healthcare and medical technology organizations. He most recently served as President – Sports Medicine, Surgical, Upper Extremities and Restorative Therapies of Zimmer Biomet Holdings, Inc. Prior to this role, Mr. Njoku served more than 18 years at Medtronic plc, a leading global healthcare technology company. Before joining Zimmer Biomet Holdings, Inc., he served as Senior Vice President and President for the Neuromodulation Operating Unit at Medtronic, leading an approximately
“We are thrilled to welcome Nnamdi to Omnicell and to have him serving in this newly created role,” stated Mr. Lipps. “Nnamdi has built an incredible reputation within the med tech industry and brings an outstanding combination of purpose-driven and values-based leadership with a solid record of driving business operations at scale. We believe his passion for harnessing the power of technology to improve healthcare access and solve unmet medical needs for all, along with his strategic insights, demonstrated execution capabilities, and leadership experience should help continue to position Omnicell for success.”
“I am excited to be joining Omnicell at this pivotal time in the Company’s rich history,” said Mr. Njoku. “Omnicell has a great track record of creating innovative solutions that are designed to address health systems more pressing issues within medication management. Omnicell’s focus on delivering outcomes-centric innovation that is intended to transform the pharmacy care delivery model inspires me. I couldn’t be happier to be part of this transformation, and I am looking forward to working with
About Nnamdi Njoku
Prior to joining Omnicell, Mr. Njoku served as President – Sports Medicine, Surgical, Upper Extremities and Restorative Therapies of Zimmer Biomet Holdings, Inc., a global medical technology leader. Prior to Zimmer Biomet, Mr. Njoku served in various executive and operational leadership roles at Medtronic plc. Prior to Medtronic, Mr. Njoku worked in operational and corporate finance roles at UnitedHealth Group, and began his career at Deloitte Consulting, helping clients optimize their operations. Mr. Njoku served as Vice Chair of People’s Center Healthcare Services, a nationally recognized community health center serving diverse communities in the
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, intelligent software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to reduce costs, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).
OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, Omnicell’s expectations regarding the new chief operating officer appointment and impact on business strategy, operational excellence and customer experience improvement efforts, our ability to deliver long-term value and statements about Omnicell’s strategy, plans, objectives, promise, purpose and guiding principles, and goals. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell’s ability to recruit and retain skilled and motivated personnel, (iii) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (iv) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (v) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (vi) delays in installations of our medication management solutions or our more complex medication packaging systems, (vii) risks related to failing to maintain expected service levels when providing our Advanced Services or retaining our Advanced Services customers, (viii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, and (x) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.
OMCL-E
View source version on businesswire.com: https://www.businesswire.com/news/home/20240925324631/en/
Kathleen Nemeth
Senior Vice President, Investor Relations
Kathleen.Nemeth@omnicell.com
650-435-3318
Source: Omnicell, Inc.
FAQ
Who is Omnicell's new Chief Operating Officer?
What is Nnamdi Njoku's background before joining Omnicell (OMCL)?
When will Nnamdi Njoku start his role at Omnicell (OMCL)?
What are Omnicell's (OMCL) expectations from the new COO appointment?
